IMMUNE · Injectable
Thymogen.
Thymus-derived immune restoration peptide
How it works
Class & mechanism.
In short
Thymogen is a two-amino-acid dipeptide bioregulator derived from thymus tissue signaling, studied for its potential to support T-cell maturation and restore immune competence in deficiency states. Research suggests it may also enhance NK cell activity and interferon secretion, with a nasal spray form studied for respiratory infection prevention. It has an unusually long Russian clinical usage history, though large-scale Western trial data remains limited.
Class
Thymic Dipeptide Bioregulator
Mechanism
Thymogen (L-Glu-L-Trp; EW dipeptide) is a synthetic dipeptide bioregulator originally isolated from the calf thymus-derived polypeptide complex Thymalin. It mimics natural thymic signaling by binding to the AACG DNA sequence motif and interacting with histone proteins, altering chromatin conformation and gene accessibility in immune cells. Functionally, Thymogen is proposed to modulate the cAMP/cGMP ratio by influencing phosphodiesterase activity — downregulating excess cyclic nucleotide catabolism — which may normalize intracellular signaling thresholds in T-lymphocytes. This is thought to drive differentiation of T-lymphocyte precursors into mature immunocompetent T-cells (evidenced by SC-1 antigen → Thy-1 antigen transition), enhance NK cell activity, stimulate interferon secretion, and activate neutrophil chemotaxis and phagocytosis without triggering autoimmune overstimulation.
Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.
Did you know
Thymogen is just two amino acids long — making it one of the simplest therapeutic peptides in existence — yet it interacts directly with DNA and is proposed to help regulate dozens of genes involved in aging, immunity, and cancer suppression, suggesting that molecular size has little bearing on biological power.
Preclinical Data
No human PK studies available.
Russian cytomedicine — minimal PK data, extremely small dipeptide
Class
Dipeptide immunomodulator (Khavinson)
Route
SC / Intranasal / Oral
Mol. Weight
218.3 Da
What we don't know
As a dipeptide, Thymogen is at the boundary between peptide and small molecule. No dedicated PK study exists. Its small size suggests rapid absorption across all routes and rapid renal clearance. Oral bioavailability may be higher than typical peptides due to the dipeptide transporter PEPT1.
Why this dosing protocol
Doses of 1-5mg SC daily for 10-day courses. Intranasal formulations are also used. The rationale for short courses with extended breaks follows the Russian bioregulator paradigm — proposed epigenetic/tissue-normalisation effects are thought to persist for months after clearance.
Empirical protocol: 1-5mg SC daily × 10 days
Safety notes
- Russian-only clinical data
Sources
Pharmacokinetic data shown for educational context. All parameters are inferred or empirically derived — no formal human PK studies exist for this compound. Individual response varies. Not a substitute for clinical dosing guidance.
Benefits
What it does.
May restore T-cell maturation and immune competence in secondary immunodeficiency states — positive outcomes reported in 94.4% of research models
May activate natural killer cell activity and enhance interferon secretion, supporting viral and cancer surveillance
Nasal spray formulation is reported to increase secretory IgA (sIgA) levels at respiratory mucosa — studied in Russian clinical trials for prevention and treatment of upper respiratory tract infections
Demonstrated anti-carcinogenic effect in rat studies: 12 months of Thymogen reduced total tumor incidence 1.5×, malignant tumors 1.7×, and hematopoietic malignancies 3.4× compared to controls
Geroprotective properties: extended maximum lifespan in treated rats by 10.4% and slowed biological aging rate (Gompertz alpha coefficient reduced from 0.0071 to 0.0041/day)
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
What this does not mean
Thymogen is a research chemical. The information on this page is educational and does not constitute medical advice, diagnosis, or treatment. Thymogen is not FDA-approved for treating immunodeficiency, preventing respiratory infections, cancer prevention, or any other use. This page does not recommend, endorse, or prescribe any compound for human use. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols or pharmaceutical recommendations.
In a 12-month controlled rat study (n=76), subcutaneous Thymogen (5 mcg/rat, 5×/week) reduced total tumor incidence 1.5-fold, malignant tumor incidence 1.7-fold, and hematopoietic malignancies 3.4-fold vs. controls; maximum lifespan of top 10% survivors extended by ~100 days (949 vs. 1048 days)
SOURCE · Anisimov & Khavinson, PubMed PMID: 11707921 — 'Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats'
Military study (Russian ARVI trial) demonstrated clinico-epidemiological efficacy of Thymogen nasal spray for prevention and treatment of acute respiratory viral infections; intranasal delivery confirmed to elevate respiratory mucosal sIgA and reduce infection incidence
SOURCE · Cited in PeptideInsight clinical review; Khavinson laboratory military clinical data (1990–2000s)
PMC review of thymalin and Thymogen molecular mechanisms confirmed: the EW dipeptide regulates heat-shock protein synthesis, cytokine production, fibrinolysis, gerontogene expression, and cell differentiation/proliferation/apoptosis — with over 25 million patients treated since 1990 registration with no reported allergic or serious side reactions
SOURCE · PMC8365293 — 'The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity' (2021)
Protocol
How to use it.
Dosing
Injectable (IM): 100–1,000 mcg (1–10 mL of 100 mcg/mL solution) daily for 3–10 days for severe immunodeficiency or acute infection recovery. Nasal spray: 25 mcg per nostril, twice daily (adults). Research protocols: 5–10 mcg/day for immune enhancement studies. Oral and topical formulations exist in Eastern European markets.
Cycle
Acute infection/immunodeficiency: 3–10 day intensive course. Maintenance and anti-aging protocols: 10–14 day cycles, 2–4 times per year. Nasal spray: continuous seasonal use permitted. Clinical use in Russia ongoing since 1990 without significant long-term safety signals.
Contraindications
When to skip it.
Excellent safety record with over 25 million patient treatments and no reported allergic reactions. Mild and rare side effects: local injection site reactions, transient nasal irritation (nasal spray). Being a dipeptide metabolized to natural amino acids (glutamic acid + tryptophan), accumulation risk is minimal. Long-term human data beyond Russian registry are limited. Physician guidance recommended for severe immunodeficiency or cancer contexts.
Always cleared with your concierge before protocol start.
Regulatory Context
FDA compounding status.
| FDA Status | Risk Level | Compounding | Key Date |
|---|---|---|---|
| No specific FDA action | 🟢 Stable | Gray zone — no specific enforcement | No pending dates |
Thymus-derived immune restoration peptide. Not on any FDA Category 1/2/3 lists. No pending PCAC review. Stable regulatory footing — no known enforcement actions.
Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.
Pricing
What it costs.
Indicative range for Thymogen, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See Thymogen pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $119–$179 USD